Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

00:00

The Probability of Success for Pelabricid

Pelabricid has a very different risk structure and profile than what you're typically used to evaluating. Most analysts put 50% probability success on their there. They all have a peak sales that's not like crazily off ours, right? I mean, somewhere around a billion. We actually think the odds are higher based on the base rate and the data and everything.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app